ABT-263

• GMP format available

ABT-263, also known as Navitoclax, is a potent and orally bioavailable inhibitor of the Bcl-2 family proteins, specifically targeting Bcl-2, Bcl-xL, and Bcl-w with Ki values of ≤0.5 nM, ≤1 nM, and ≤1 nM, respectively.

Key features and applications include:

• High Selectivity: Selectively inhibits Bcl-2, Bcl-xL, and Bcl-w over other Bcl-2 family proteins.
• Potency: Demonstrates strong inhibitory effects with low Ki values.
• Induce Apoptosis: Promotes apoptosis in various cancer cell lines, including small cell lung cancer (SCLC), leukemia, and lymphoma.
• Enhance Chemotherapy: Synergizes with chemotherapeutic agents to enhance their efficacy.
• Reduce Tumor Growth: Effective in mouse xenograft models of SCLC and acute lymphocytic leukemia (ALL).

Relevant disease states include:

• Cancer: Active in models of SCLC, leukemia, lymphoma, and other cancers.
• Viral Infections: Induces apoptosis in influenza A-infected retinal pigment epithelial cells.
• Inflammation: Reduces inflammation and viral-induced senescence in SARS-CoV-2 infection.